Similar articles

• [Prostaglandin treatment of ductus-dependent congenital heart defects].

  Olsson B, Björkhem G, Lundström NR. Olsson B, et al. Lakartidningen. 1984 Oct 3;81(40):3619-22. Lakartidningen. 1984. PMID: 6541738 Swedish. No abstract available.
• [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].

  Lillquist K. Lillquist K. Ugeskr Laeger. 1979 Jul 9;141(28):1915-6. Ugeskr Laeger. 1979. PMID: 473414 Danish. No abstract available.
• Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease.

  Yokota M, Muraoka R, Aoshima M, Nomoto S, Shiraishi Y, Kyoku I, Kitano M, Shimada I, Nakano H, Ueda K, et al. Yokota M, et al. J Thorac Cardiovasc Surg. 1985 Sep;90(3):399-403. J Thorac Cardiovasc Surg. 1985. PMID: 4033176
• The ductus arteriosus: why and how to manipulate its patency.

  Drummond WH, Bucciarelli RL, Gessner IH. Drummond WH, et al. J Fla Med Assoc. 1983 Sep;70(9):788-93. J Fla Med Assoc. 1983. PMID: 6355376 Review. No abstract available.
• Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.

  Heymann MA, Clyman RI. Heymann MA, et al. Pharmacotherapy. 1982 May-Jun;2(3):148-55. doi: 10.1002/j.1875-9114.1982.tb04522.x. Pharmacotherapy. 1982. PMID: 6763200 Review.